NCT05189925View on ClinicalTrials.gov

NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 22, 2022

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2026

Conditions

Chronic Granulomatous DiseaseInfection

Interventions

BIOLOGICAL

gp91 Grans

Adults with gp91phox-deficient CGD without systemic infection will participate in a dose escalation trial to identify the MTD (the most effective yet safe dose) of gp91 Grans IV infusion.

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH